AbbVie Reports long-term follow-up Data for Donanemab in Hepatocellular carcinoma

AbbVie today announced long-term follow-up results for donanemab in patients with hepatocellular carcinoma. The study demonstrated that donanemab improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of hepatocellular carcinoma and support the continued development of donanemab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.